TY - JOUR
T1 - Development and application of 3D cardiac tissues derived from human pluripotent stem cells
AU - Ohno, Masatoshi
AU - Tani, Hidenori
AU - Tohyama, Shugo
N1 - Publisher Copyright:
© 2025 The Japanese Society for the Study of Xenobiotics
PY - 2025/2
Y1 - 2025/2
N2 - Recently human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have become an attractive platform to evaluate drug responses for cardiotoxicity testing and disease modeling. Moreover, three-dimensional (3D) cardiac models, such as engineered heart tissues (EHTs) developed by bioengineering approaches, and cardiac spheroids (CSs) formed by spherical aggregation of hPSC-CMs, have been established as useful tools for drug discovery and transplantation. These 3D models overcome many of the shortcomings of conventional 2D hPSC-CMs, such as immaturity of the cells. Cardiac organoids (COs), like other organs, have also been studied to reproduce structures that resemble a heart in vivo more closely and optimize various culture conditions. Heart-on-a-chip (HoC) developed by a microfluidic chip-based technology that enables real-time monitoring of contraction and electrical activity, provides multifaceted information that is essential for capturing natural tissue development in vivo. Recently, 3D experimental systems have been developed to study organ interactions in vitro. This review aims to discuss the developments and advancements of hPSC-CMs and 3D cardiac tissues.
AB - Recently human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have become an attractive platform to evaluate drug responses for cardiotoxicity testing and disease modeling. Moreover, three-dimensional (3D) cardiac models, such as engineered heart tissues (EHTs) developed by bioengineering approaches, and cardiac spheroids (CSs) formed by spherical aggregation of hPSC-CMs, have been established as useful tools for drug discovery and transplantation. These 3D models overcome many of the shortcomings of conventional 2D hPSC-CMs, such as immaturity of the cells. Cardiac organoids (COs), like other organs, have also been studied to reproduce structures that resemble a heart in vivo more closely and optimize various culture conditions. Heart-on-a-chip (HoC) developed by a microfluidic chip-based technology that enables real-time monitoring of contraction and electrical activity, provides multifaceted information that is essential for capturing natural tissue development in vivo. Recently, 3D experimental systems have been developed to study organ interactions in vitro. This review aims to discuss the developments and advancements of hPSC-CMs and 3D cardiac tissues.
KW - Cardiac organoids
KW - Cardiac spheroids
KW - Drug discovery
KW - Engineered heart tissue
KW - Heart on a chip
KW - Human pluripotent stem cells derived cardiomyocytes
UR - http://www.scopus.com/inward/record.url?scp=85215414457&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85215414457&partnerID=8YFLogxK
U2 - 10.1016/j.dmpk.2024.101049
DO - 10.1016/j.dmpk.2024.101049
M3 - Review article
AN - SCOPUS:85215414457
SN - 1347-4367
VL - 60
JO - Drug Metabolism and Pharmacokinetics
JF - Drug Metabolism and Pharmacokinetics
M1 - 101049
ER -